2022
DOI: 10.1038/s41598-022-26195-x
|View full text |Cite
|
Sign up to set email alerts
|

Engineering a two-gene system to operate as a highly sensitive biosensor or a sharp switch upon induction with β-estradiol

Abstract: The human estrogen receptor has been used for about thirty years, in the yeast S. cerevisiae, as a component of chimeric transcription factors. Its ligand, β-estradiol, permits to control the protein translocation into the nucleus and, as a consequence, the expression of the gene(s) targeted by the synthetic transcription factor. Activators that are orthogonal to the yeast genome have been realized by fusing the human estrogen receptor to an activation and a DNA-binding domain from bacteria, viruses, or higher… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1

Citation Types

0
2
0

Year Published

2023
2023
2024
2024

Publication Types

Select...
4
1

Relationship

2
3

Authors

Journals

citations
Cited by 5 publications
(2 citation statements)
references
References 39 publications
0
2
0
Order By: Relevance
“…Each of the other two systems demanded to assemble two new TUs. One TU was for TtLcc1 expression under the control of a synthetic regulated promoter, either 2xlex2Op_pCYC1core [ 25 ] or pCYC1min_tetOp [ 26 ] (see Fig. 3 A and S3B-D).…”
Section: Resultsmentioning
confidence: 99%
“…Each of the other two systems demanded to assemble two new TUs. One TU was for TtLcc1 expression under the control of a synthetic regulated promoter, either 2xlex2Op_pCYC1core [ 25 ] or pCYC1min_tetOp [ 26 ] (see Fig. 3 A and S3B-D).…”
Section: Resultsmentioning
confidence: 99%
“…We tested Cas12c behavior as a signal carrier in synthetic gene hybrid gates—where translation was downregulated by up-to-two riboswitches responding to tetracycline ( Kötter et al, 2009 ). For a comparison, we implemented several different hybrid gates that made use of transcription factors based on either type V denAsCas12a ( Kleinstiver et al, 2019 ; Yu and Marchisio, 2021 ) or LexA-HBD (hER) (i.e., the bacterial protein LexA fused to the hormone-binding domain of the human estrogen receptor) ( Louvion et al, 1993 ; Zhou et al, 2022 ). Alternatively, we also employed promoters regulated by internal pathways (e.g., the GAL1 promoter).…”
Section: Introductionmentioning
confidence: 99%